1/15/2020 8:44:15 AM
Natera Announces Agreement With National Cancer Center Japan To Launch CIRCULATE-IDEA Trial In Japan
1/13/2020 9:28:16 AM
Natera Reports New Early Priority Date CfDNA Patent, Files Suit Against CareDx
1/9/2020 9:07:48 AM
Natera To Evaluate Outcomes In 1,000 Signatera Patients With Stage II-III Colorectal Cancer
11/27/2019 8:22:35 AM
Natera Announces Results Of A Study Published In The Journal Of Prenatal Diagnosis
10/16/2019 10:32:33 PM
Natera Prices Underwritten Public Offering Of 5.71 Mln Shares At $35.00/shr
8/29/2019 9:21:06 AM
Natera Appoints Rowan Chapman To Its Board
5/9/2019 4:24:34 PM
Natera Q1 Loss/share $0.54 Vs. Loss $0.61 Year Ago
5/6/2019 11:57:39 AM
FDA Grants Breakthrough Device Designation To Natera's Signatera Test
4/17/2019 11:44:59 PM
Natera Announces Pricing Of Follow-On Offering Of 5.26 Mln Shares At $19/Shr
4/10/2019 8:05:00 AM
Natera Plans To Commercialize Tumor Whole Exome Sequencing From Plasma
3/26/2019 8:09:44 AM
Natera To Partner With AMAL Therapeutics On Clinical Trial Focused On Stage IV Colorectal Cancer
3/12/2019 4:19:01 PM
Natera Q4 Loss/share $0.51 Vs. Loss $0.90 Year Ago
3/11/2019 6:07:46 AM
Natera And BGI Genomics Announce $50 Mln Partnership To Commercialize Signatera Oncology Test In China
2/1/2019 7:31:35 AM
Natera Announces Partnership With Thermo Fisher Scientific's One Lambda Brand